PP Tak

1.2k total citations
38 papers, 910 citations indexed

About

PP Tak is a scholar working on Rheumatology, Molecular Biology and Oncology. According to data from OpenAlex, PP Tak has authored 38 papers receiving a total of 910 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Rheumatology, 11 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in PP Tak's work include Rheumatoid Arthritis Research and Therapies (15 papers), Salivary Gland Disorders and Functions (6 papers) and Systemic Lupus Erythematosus Research (6 papers). PP Tak is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (15 papers), Salivary Gland Disorders and Functions (6 papers) and Systemic Lupus Erythematosus Research (6 papers). PP Tak collaborates with scholars based in Netherlands, United States and United Kingdom. PP Tak's co-authors include Nienke Roescher, GG Illei, C A Wijbrandts, A. H. Zwinderman, D M Gerlag, Rogier M. Thurlings, Koen Vos, Maarten C. Kraan, Helen Weedon and Michael Ahern and has published in prestigious journals such as Annals of the Rheumatic Diseases, Arthritis Research & Therapy and Oral Diseases.

In The Last Decade

PP Tak

34 papers receiving 885 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
PP Tak Netherlands 9 467 256 208 208 157 38 910
A Trabandt Germany 17 589 1.3× 329 1.3× 223 1.1× 186 0.9× 111 0.7× 31 1.2k
Manuel J. Del Rey Spain 18 263 0.6× 368 1.4× 320 1.5× 67 0.3× 99 0.6× 49 1.2k
Yemil Atisha‐Fregoso Mexico 17 579 1.2× 468 1.8× 114 0.5× 72 0.3× 154 1.0× 44 921
Jolien Suurmond Netherlands 18 343 0.7× 785 3.1× 178 0.9× 176 0.8× 127 0.8× 23 1.1k
Thomas Karonitsch Austria 19 464 1.0× 355 1.4× 236 1.1× 60 0.3× 56 0.4× 41 984
Mitsuko Sasai Japan 7 423 0.9× 408 1.6× 241 1.2× 171 0.8× 71 0.5× 9 1.2k
Takeo Isozaki Japan 20 363 0.8× 324 1.3× 244 1.2× 56 0.3× 87 0.6× 55 930
Jianping Guo China 18 322 0.7× 357 1.4× 320 1.5× 89 0.4× 35 0.2× 50 964
Elisa Corsiero United Kingdom 12 291 0.6× 468 1.8× 340 1.6× 86 0.4× 91 0.6× 25 995
Kiyoaki Tanimoto Japan 19 314 0.7× 512 2.0× 346 1.7× 111 0.5× 306 1.9× 54 1.1k

Countries citing papers authored by PP Tak

Since Specialization
Citations

This map shows the geographic impact of PP Tak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by PP Tak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites PP Tak more than expected).

Fields of papers citing papers by PP Tak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by PP Tak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by PP Tak. The network helps show where PP Tak may publish in the future.

Co-authorship network of co-authors of PP Tak

This figure shows the co-authorship network connecting the top 25 collaborators of PP Tak. A scholar is included among the top collaborators of PP Tak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with PP Tak. PP Tak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Safy, M., et al.. (2015). A8.10 The effect of rituximab treatment on B and T cell subsets in lymphoid tissues of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 74. A85–A85. 1 indexed citations
2.
Roescher, Nienke, et al.. (2011). TACI‐Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non‐obese diabetic mice. Oral Diseases. 18(4). 365–374. 20 indexed citations
3.
Roescher, Nienke, et al.. (2011). Temporal changes in salivary glands of non‐obese diabetic mice as a model for Sjögren’s syndrome. Oral Diseases. 18(1). 96–106. 43 indexed citations
4.
5.
Roescher, Nienke, PP Tak, & GG Illei. (2009). Cytokines in Sjögren’s syndrome. Oral Diseases. 15(8). 519–526. 139 indexed citations
6.
Keystone, Edward, Paul Emery, Charles Peterfy, et al.. (2008). Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Annals of the Rheumatic Diseases. 68(2). 216–221. 173 indexed citations
7.
Thurlings, Rogier M., Koen Vos, C A Wijbrandts, et al.. (2007). Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Annals of the Rheumatic Diseases. 67(7). 917–925. 254 indexed citations
8.
Mineshiba, Fumi, Marc R. Kok, Charles Zheng, et al.. (2006). NOD mouse model for Sjögren's syndrome: lack of longitudinal stability. Oral Diseases. 12(6). 566–572. 28 indexed citations
9.
Kruithof, Elli, Leen De Rycke, Filip De Keyser, et al.. (2005). Identification of synovial biomarkers of response to treatment in spondyloarthropathy. Ghent University Academic Bibliography (Ghent University). 52(9). 633. 1 indexed citations
10.
11.
Kraan, Maarten C., et al.. (2004). Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Annals of the Rheumatic Diseases. 63(9). 1056–1061. 44 indexed citations
12.
May, Michael J., et al.. (2004). The effects of NF-κB inhibition by a NEMO binding domain peptide in vitro and in vivo. Arthritis Research. 6(Suppl 1). 51–51. 1 indexed citations
13.
Holten, Judith van, et al.. (2004). Local interferon-β gene therapy ameliorates adjuvant arthritis in rats. Arthritis Research. 6(Suppl 1). 54–54. 1 indexed citations
14.
Kok, Marc R., Antonis Voutetakis, Seiichi Yamano, et al.. (2004). Host immune responses to salivary gland administration of recombinant adeno-associated virus serotype 2 vectors. Arthritis Research. 6(Suppl 1). 78–78. 1 indexed citations
15.
16.
Sattonnet‐Roche, Pascale, et al.. (2002). The effects of interferon-β (IFN-β) treatment on synovial cytokine expression in collagen induced arthritis in DBA/1 mice. Arthritis Research. 4(Suppl 1). 62–62. 1 indexed citations
17.
18.
Tak, PP. (2001). IKKbeta and p53 as therapeutic targets for arthritis. Arthritis Research. 3(Suppl 1). P10–P10. 1 indexed citations
19.
Vossenaar, E.R., et al.. (2001). Expression of citrullin-containing antigens in RA synovium. Arthritis Research & Therapy. 3(S2). 8 indexed citations
20.
Tak, PP, et al.. (2000). Disease duration and the expression of chemokines and matrix metalloproteinases in rheumatoid arthritis. Arthritis & Rheumatism. 43. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A Trabandt Breakdown of academic impact, for papers by Manuel J. Del Rey Breakdown of academic impact, for papers by Yemil Atisha‐Fregoso Breakdown of academic impact, for papers by Jolien Suurmond Breakdown of academic impact, for papers by Thomas Karonitsch Breakdown of academic impact, for papers by Mitsuko Sasai Breakdown of academic impact, for papers by Takeo Isozaki Breakdown of academic impact, for papers by Jianping Guo Breakdown of academic impact, for papers by Elisa Corsiero Breakdown of academic impact, for papers by Kiyoaki Tanimoto
Rankless by CCL
2026